Use of MKC-442 in combination with other antiviral agents

A method for the treatment of a patient infected with HIV, comprising administering an effective treatment amount of MKC-442 or its pharmaceutically acceptable salt in combination or alternation with a compound selected from the group consisting of:

• indinavir, nelfinavir, saquinavir, amprenavir, and DMP-450 or its pharmaceutically acceptable salt.

A method for the treatment of a patient infected with HIV, comprising administering an effective treatment amount of MKC-442 or its pharmaceutically acceptable salt in combination or alternation with a compound selected from the group consisting of abacavir, FTC, or 3TC or its pharmaceutically acceptable salt.

A method for the treatment of a patient infected with HIV, comprising administering an effective treatment amount of MKC-442 or its pharmaceutically acceptable salt in combination or alternation with a compound selected from the group consisting of DMP-266, delavirdine, and nevirapine or its pharmaceutically acceptable salt.

A pharmaceutical composition for the treatment of a patient infected with HIV, comprising an effective treatment amount of MKC-442 or its pharmaceutically acceptable salt in combination with a protease inhibitor, or its pharmaceutically acceptable salt.

A pharmaceutical composition for the treatment of a patient infected with HIV, comprising an effective treatment amount of MKC-442 or its pharmaceutically acceptable salt in combination or alternation with a compound selected from the group consisting of:

• indinavir, nelfinavir, saquinavir, amprenavir, and DMP-450 or its pharmaceutically acceptable salt.

A pharmaceutical composition for the treatment of a patient infected with HIV, comprising an effective treatment amount of MKC-442 or its pharmaceutically acceptable salt in combination or alternation with a compound selected from the group consisting of abacavir, FTC, or 3TC or its pharmaceutically acceptable salt.

A pharmaceutical composition for the treatment of a patient infected with HIV, comprising an effective treatment amount of MKC-442 or its pharmaceutically acceptable salt in combination with a compound selected from the group consisting of DMP-266, delavirdine, and nevirapine or its pharmaceutically acceptable salt.